JITC

Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis
Siqi Zhang, Mengge Zheng, Deheng Nie, Lili Xu, Huimin Tian, Mengmeng Wang, Wenjia Liu, Zhenbang Feng, Fujun Han

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005158; DOI: 10.1136/jitc-2022-005158
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation
Guoliang Deng, Lisha Zhou, Binglin Wang, Xiaofan Sun, Qinchang Zhang, Hongqi Chen, Ning Wan, Hui Ye, Xiaoqi Wu, Dongdong Sun, Yang Sun, Haibo Cheng

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e004874; DOI: 10.1136/jitc-2022-004874
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
Landon C Brown, Jason Zhu, Kunal Desai, Emily Kinsey, Chester Kao, Yong Hee Lee, Sarabjot Pabla, Matthew K Labriola, Jennifer Tran, Konstantin H Dragnev, Laura J Tafe, Farshid Dayyani, Rajan T Gupta, Shannon McCall, Daniel J George, Sean T Glenn, Mary K Nesline, Saby George, Matthew Zibelman, Carl Morrison, Moshe C Ornstein, Tian Zhang

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005249; DOI: 10.1136/jitc-2022-005249
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
Stine Emilie Weis-Banke, Thomas Landkildehus Lisle, Maria Perez-Penco, Aimilia Schina, Mie Linder Hübbe, Majken Siersbæk, Morten Orebo Holmström, Mia Aaboe Jørgensen, Inge Marie Svane, Özcan Met, Niels Ødum, Daniel Hargbøl Madsen, Marco Donia, Lars Grøntved, Mads Hald Andersen

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005326; DOI: 10.1136/jitc-2022-005326
Localized ablative immunotherapy drives de novo CD8⁺ T-cell responses to poorly immunogenic tumors
Ashley R Hoover, Saghar Kaabinejadian, Jason R Krawic, Xiao-Hong Sun, Abdul Rafeh Naqash, Qian Yin, Xinbo Yang, K Christopher Garcia, Mark M Davis, William H Hildebrand, Wei R Chen

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e004973; DOI: 10.1136/jitc-2022-004973
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Maria Vieito, Rowan E Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E Janik, Jason Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M Mehnert

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e004235; DOI: 10.1136/jitc-2021-004235
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
Frank M Speetjens, Marij J P Welters, Marije Slingerland, Mariette I E van Poelgeest, Peggy J de Vos van Steenwijk, Inge Roozen, Sanne Boekestijn, Nikki M Loof, Gijs G Zom, A Rob P M Valentijn, Willem-Jan Krebber, Nico J Meeuwenoord, Catharina A H Janssen, Cornelis J M Melief, Gijs A van der Marel, Dmitri V Filippov, Sjoerd H van der Burg, Hans Gelderblom, Ferry Ossendorp

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005016; DOI: 10.1136/jitc-2022-005016
Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages
Marine Monnier, Léa Paolini, Emeline Vinatier, Alberto Mantovani, Yves Delneste, Pascale Jeannin

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005560; DOI: 10.1136/jitc-2022-005560
Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
Xia Liu, Fusheng Si, David Bagley, Feiya Ma, Yuanqin Zhang, Yan Tao, Emily Shaw, Guangyong Peng

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005020; DOI: 10.1136/jitc-2022-005020
Combining precision oncology and immunotherapy by targeting the MALT1 protease
Thorsten R Mempel, Daniel Krappmann

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005442; DOI: 10.1136/jitc-2022-005442

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages